Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 208-212

  Roger, Claire ^a,b   Nucci, Bastian ^a   Louart, Benjamin ^a,b   Friggeri, Arnaud ^c   Knani, Haroun ^a   Evrard, Alexandre ^a   Lavigne, Jean Philippe ^a,d   Allaouchiche, Bernard ^c   Lefrant, Jean Yves ^a,b   Roberts, Jason A ^e   Muller, Laurent ^a,b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b University of Montpellier 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; GENTAMICIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; HUMAN; INTENSIVE CARE UNIT; LIMIT OF QUANTITATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; SEPSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; AGED; CHEMISTRY; CRITICAL ILLNESS; FRANCE; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; SERUM; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; FRANCE; GENTAMICINS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEPSIS; SERUM; YOUNG ADULT;

EID: 84960095260     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv291     Document Type: Article

References (20)

1. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 Crit Care Med 2013; 41: 580-637.
2. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
3. Kumar A, Safdar N, Kethireddy S et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/ meta-regression study. Crit Care Med 2010; 38: 1651-64.
4. Kumar A, Zarychanski R, Light B et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-85.
5. Brunkhorst FM, Oppert M, Marx G et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307: 2390-9.
6. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011; 55: 2528-31.
7. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
8. Agence Nationale de Sécurité du Mé dicament. Bon usage des aminosides administrés par voie injectable: gentamycine, tobramycine, netimicine, amikacine-Mise au point. http://ansm.sante.fr/Mediatheque/ Publications/Recommandations-Medicaments.
9. Taccone FS, Laterre PF, Spapen H et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
10. de Montmollin E, Bouadma L, Gault N et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 2014; 40: 998-1005.
11. Blackburn LM, Tverdek FP, Hernandez M et al. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. Int J Antimicrob Agents 2015; 45: 46-53.
12. Roger C, Nucci B, Molinari N et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents 2015; 46: 21-7.
13. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51; quiz 859.
14. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-63.
15. Vincent JL, de Mendonca A, Cantraine F et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsisrelated problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-800.
16. Mehta RL, Kellum JA, Shah SVet al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
17. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
18. Lefrant JY, Muller L, Raillard A et al. Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: a multicenter study. Ann Fr Anesth Reanim 2010; 29: 621-8.
19. Galvez R, Luengo C, Cornejo R et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38: 146-51.
20. Duszynska W, Taccone FS, Hurkacz M et al. Therapeutic drug monitoring of amikacin in septic patients. Crit Care 2013; 17: R165.